India says shipments of hydroxychloroquine will resume after US exerts pressure
Move comes 24 hours after US President warns of "retaliation" if export ban was not lifted
India has relaxed an export ban on anti-malarial drug hydroxychloroquine just 24 hours after US President Donald Trump warned of “retaliation” if the measure was not lifted.
“After having confirmed the availability of medicines for all possible contingencies currently envisaged, these restrictions have been largely lifted,” said Indian Ministry of External Affairs (MEA) spokesman Anurag Srivastava in a statement Tuesday. “With regard to paracetamol and hydroxychloroquine, they will be kept in a licensed category and their demand position [will] be continuously monitored.”
He added that the current stock position of the drugs meant Indian pharmaceutical manufacturers should be able to meet the export commitments they had contracted.
The MEA also said India would be supplying paracetamol and hydroxychloroquine to neighbouring countries dependent on its medicines supply.
US President Donald Trump had telephoned Indian Prime Minister Narendra Modi on Saturday, asking him to lift an existing ban on exports of hydroxychloroquine, which the US administration has touted as a potential treatment for sufferers of COVID-19.
Earlier that day, India’s Directorate General of Foreign Trade had reinforced the blanket ban on hydroxychloroquine exports “without any exception”.
“The two leaders agreed to remain in touch on the issue of global supply chains for critical pharmaceuticals and medical supplies and to ensure they continue to function as smoothly as possible during the global health crisis,” said White House spokesman Judd Deer in a tweet on Saturday after the phone conversation.
In a tweet posted on Monday, Dr Sharvil Patel, managing director of Zydus Cadila, the largest supplier of hydroxychloroquine to the US market, said the company was ramping up production to meet requirements.
“Our concern is to make the drug available to those who require it,” he said.
On Monday, India lifted export restrictions on twelve active pharmaceutical ingredients and their associated finished products with immediate effect, according to the country’s Directorate General of Foreign Trade (DGFT).
The temporary restrictions were imposed on March 3 to ensure domestic supply amid slowing imports from China, a key producer of the ingredients, as the growing coronavirus pandemic impacted global pharmaceutical supply chains.
The list of products freed from export restrictions includes antibiotics clindamycin and erythromycin, anti-infective tinidazole and some vitamins but hydroxychloroquine and over-the-counter painkiller paracetamol were notable omissions.
While the Indian government has so far provided no reason for the overturning of the restrictions, API supply from China is understood to have restarted as the country comes out of lockdown.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance